Cancer Trade-offs

In recommending approval of two cancer compounds with safety concerns last week, FDA's Oncologic Drugs Advisory Committee signaled that having more treatment options trumped potential risks, and that doctors should be left to make the benefit-risk choice.

ODAC voted 10-0 that Votrient pazopanib from GlaxoSmithKline plc had a positive benefit/risk profile for patients with renal cell carcinoma despite the identification of four possible Hy's law cases signaling potential liver toxicity...